A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony rozpoznaniem rak płuc małokomórkowy w zaawansowanym stadium
- •Dobry ogólny stan zdrowia (wskaźnik sprawności 0 lub 1)
- •Prawidłowe wyniki badań krwi i funkcji narządów
✗ Disqualifies
- •Wcześniejsze leczenie przeciwnowotworowe tego rodzaju raka
- •Wcześniejsza terapia skierowana na B7H3 lub inhibitory topoisomerazy I
- •Aktywne przerzuty do mózgu lub nacisk na rdzeń kręgowy
- •Choroby płuc związane z zapaleniem (międzyatkowe zapalenie płuc)
- •Poważne choroby serca (w tym niewydolność serca klasy II-IV)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (38)
Site 1001
Washington D.C., United States
Site 1009
Plantation, United States
Site 1004
Louisville, United States
Site 1005
Houston, United States
Site 1002
Fairfax, United States
Site 1203
Edegem, Belgium
Site 1201
Namur, Belgium
Site 1402
Nice, France
Site 1404
Paris, France
Site 1403
Suresnes, France
Site 1601
Kalocsa, Hungary
Site 1705
Candiolo, Italy
Site 1703
Meldola, Italy
Site 1702
Ravenna, Italy
Site 1802
Otwock, Poland
Site 1804
Poznan, Poland
Site 1801
Przemyśl, Poland
Site 1904
Bucharest, Romania
Site 1903
Cluj-Napoca, Romania
Site 1901
Craiova, Romania
Site 2013
Badajoz, Spain
Site 2012
Badalona, Spain
Site 2014
Barcelona, Spain
Site 2003
Barcelona, Spain
Site 2006
Barcelona, Spain
Site 2001
Barcelona, Spain
Site 2007
Girona, Spain
Site 2002
Madrid, Spain
Site 2005
Madrid, Spain
Site 2019
Madrid, Spain
Site 2004
Madrid, Spain
Site 2011
Madrid, Spain
Site 2010
Manresa, Spain
Site 2008
Seville, Spain
Site 2009
Valencia, Spain
Site 2015
Valencia, Spain
Site 2203
Edinburgh, United Kingdom
Site 2201
London, United Kingdom
Trial contact
MediLink Study Team
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.